Skip to content
Study details
Enrolling now

Apixaban or Enoxaparin After Head and Neck Cancer Surgery

Kiranya Arnold
NCT IDNCT07189897ClinicalTrials.gov data as of Apr 2026
Phase

Phase 4

Target enrollment

76

Study length

about 2.2 years

Ages

18–89

Locations

1 site in NY

What this study is about

Researchers are testing if apixaban (a pill) can be used instead of enoxaparin (a shot) to prevent blood clots after head and neck cancer surgery. The trial will also look at how easy it is for patients to take apixaban compared to enoxaparin, and whether they stick with the treatment plan. Participants will take either apixaban or enoxaparin for 10 days after surgery, keep track of their medication, and have regular checkups.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Apixaban
  • 2.Take Enoxaparin

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
OralInjection / IV

How treatment is administered

Treatment Assignment
Randomized (Open Label)

You are randomly assigned, but you will know your treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

apixaban (Factor Xa inhibitor; prevents clot formation), enoxaparin (Low molecular weight heparin; inactivates clotting factor Xa)

Drug routes

oral, injection

Body systems

Oncology